Health Canada releases Remdesivir adverse event reports

Remdesivir maims and kills

Update — Gilead’s reports here

In August 2022 an Access to Information request was filed for serious adverse events associated with remdesivir in Canadian hospitals. Also known as veklury, remdesivir is Gilead’s failed ebola drug, dubiously repurposed for treating covid. The drug is known to pose extreme danger to kidneys.

In a 2019 ebola clinical trial, 93 of 175 people given remdesivir (53%) died, including 29 individuals with ‘low viral load’ — see table 2. The drug was pulled from the trial for this reason. Wrongful death lawsuits are forming in the U.S. to sue hospitals where covid patients - or patients who came to the hospital for something else and told they had covid - were killed by the drug. In some cases patients were physically restrained to a bed for days or weeks with remdesivir administered by IV drip. Virtually all who died were isolated in a room and denied access to family members, friends or legal representation.

These allegations are yet to be proven in a court of law, but corroborating horror stories are out there — see for example the testimony of,

• Nurse Erin Olszewski (starts at 29:53)

• Nurse Nicole Sirotek

• Patient Greta Crawford (starts at 1:01:55)

• Dr. Peter McCullough

8 months following the alarming ebola clinical trial results in the New England Journal of Medicine, Health Canada authorized remdesivir for people as young as 12.

In September 2022 Health Canada provided a partial interim release of its remdesivir reports:

Health Canada interim release package re Remdesivir adverse events - 8 Sep 2022 - 114 pages

11.5MB ∙ PDF file

Download

Download

Below find excerpts of serious adverse events associated with remdesivir, reported by hospitals to Health Canada.

Deaths and serious injuries follow, including a bizarre suicide and an injured infant. Remdesivir is administered via intravenous drip.

84 year old man, page 1

Same man, page 8

Same man, page 9

50 year old woman, page 13

Same woman, page 19

78 year old woman, page 23

Same woman, page 24

Same woman, page 25

49 year old man, page 30

Same man, page 34

55 year old woman, page 38

Same woman, page 38

Same woman, page 41

75 year old man, page 47

Same man, page 48

51 year old woman, page 50

Same woman, page 52

79 year old woman, page 57

Same woman, page 65

93 year old woman, page 69

Same woman, page 69. “Hypersensitivity reaction: chills at the end of infusion, then nausea, vomiting, tachycardia 120 bpm, transferred to emergency”

91 year old woman, page 73

Same woman, page 74

UNAUTHORIZED USE, 2 year old boy, heart rate dropped to 38 bpm, page 76 — this report is expanded upon here

Same boy, page 77

75 year old woman, page 78

Same woman, page 80

67 year old woman, page 84

Same woman, page 102, severe bradycardia (low heart rate)

70 year old man, page 106

Same man, page 111

Time to cease remdesivir? Yes. It should should never have been administered in the first place.

More reports coming.

Followup story here